No ratings yet
Taught by or worked with Andrew? Your rating helps other students choose.
Andrew Albert Verdegaal, PhD, is a Postdoctoral Associate in the Department of Microbial Pathogenesis at Yale School of Medicine, where he conducts research in the Goodman Lab. He earned his PhD in Microbiology from Yale University in 2024, with a dissertation titled “Impact of Medical Drugs on Microbiome Dynamics.” Prior to his doctoral studies, he received an MA in Molecular, Cellular, and Developmental Biology and a BS in Cell and Developmental Biology, both from the University of California, Santa Barbara.
Verdegaal’s research centers on the interactions between medical drugs, the gut microbiome, and bacterial metabolism. His work has contributed to understanding how drugs influence microbiome composition and function, including studies on microbial transformation of dietary xenobiotics and drug-microbiome-drug interactions relevant to conditions such as Parkinson’s disease. He has co-authored peer-reviewed publications in journals including Nature Microbiology and Cell. Verdegaal previously held affiliations with the Wyss Institute for Biologically Inspired Engineering at Harvard University. His professional email address is andrew.verdegaal@yale.edu.
Explore Yale School of Medicine's discovery that COMT inhibitors disrupt gut bacteria, reducing levodopa efficacy in Parkinson's patients. Implications for U.S. university research.
Photo by Precondo CA on Unsplash
Photo by Brecht Corbeel on Unsplash
Photo by Anne Nygård on Unsplash
Photo by Kelly Sikkema on Unsplash
Photo by Markus Winkler on Unsplash
Photo by Philip Strong on Unsplash
